Digoxin inhibits PDGF-BB-induced VSMC proliferation and migration through an increase in ILK signaling and attenuates neointima formation following carotid injury

Yan,Gaoliang; Wang,Qingjie; Hu,Shengda; Wang,Dong; Qiao,Yong; Ma,Genshan; Tang,Chengchun; Gu,Yuchun

doi:10.3892/ijmm.2015.2320

Digoxin inhibits PDGF-BB-induced VSMC proliferation and migration through an increase in ILK signaling and attenuates neointima formation following carotid injury

Authors:
- Gaoliang Yan
- Qingjie Wang
- Shengda Hu
- Dong Wang
- Yong Qiao
- Genshan Ma
- Chengchun Tang
- Yuchun Gu
View Affiliations

Affiliations: Department of Cardiology, Zhongda Hospital of Southeast University Medical School, Nanjing, Jiangsu 210009, P.R. China, Institute of Molecular Medicine (IMM), Peking University, Beijing 100190, P.R. China
Published online on: August 21, 2015 https://doi.org/10.3892/ijmm.2015.2320
Pages: 1001-1011
Copyright: © Yan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The increased proliferation and migration of vascular smooth muscle cells (VSMCs) are key events in the development of artery restenosis following percutaneous coronary intervention. Digoxin has long been used in the treatment of heart failure and has been shown to inhibit the proliferation of cancer cells through multiple pathways. However, the potential role of digoxin in the regulation of VSMC proliferation and migration and its effectiveness in the treatment of cardiovascular diseases, such as restenosis, remains unexplored. In the present study, we demonstrate that digoxin-induced growth inhibition is associated with the downregulation of CDK activation and the restoration of p27Kip1 levels in platelet-derived growth factor (PDGF)-stimulated VSMCs. In addition, we found that digoxin restored the PDGF‑BB-induced inhibition of integrin linked kinase (ILK) expression and prevented the PDGF‑BB-induced activation of glycogen synthase kinase (GSK)-3β. Furthermore, digoxin inhibited adhesion molecule and extracellular matrix relative protein expression. Finally, we found that digoxin significantly inhibited neointima formation, accompanied by a decrease in cell proliferation following vascular injury in rats. These effects of digoxin were shown to be mediated, at least in part, through an increase in ILK/Akt signaling and a decrease in GSK-3β signaling in PDGF‑BB-stimulated VSMCs. In conclusion, our data demonstrate that digoxin exerts an inhibitory effect on the PDGF‑BB-induced proliferation, migration and phenotypic modulation of VSMCs, and prevents neointima formation in rats. These observations indicate the potential therapeutic application of digoxin in the treatment of cardiovascular diseases, such as restenosis.

View Figures

View References

1	Davis-Dusenbery BN, Wu C, Hata A and Sessa WC: Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation. Arterioscler Thromb Vasc Biol. 31:2370–2377. 2011. View Article : Google Scholar : PubMed/NCBI
2	Goel SA, Guo LW, Liu B and Kent KC: Mechanisms of post-intervention arterial remodelling. Cardiovasc Res. 96:363–371. 2012. View Article : Google Scholar : PubMed/NCBI
3	Weintraub WS: The pathophysiology and burden of restenosis. Am J Cardiol. 100:3K–9K. 2007. View Article : Google Scholar : PubMed/NCBI
4	Dzau VJ, Braun-Dullaeus RC and Sedding DG: Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat Med. 8:1249–1256. 2002. View Article : Google Scholar : PubMed/NCBI
5	Raines EW: PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 15:237–254. 2004. View Article : Google Scholar : PubMed/NCBI
6	Ahmed A, Pitt B, Rahimtoola SH, Waagstein F, White M, Love TE and Braunwald E: Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: A propensity-matched study of the DIG trial. Int J Cardiol. 123:138–146. 2008. View Article : Google Scholar
7	Pervaiz MH, Dickinson MG and Yamani M: Is digoxin a drug of the past? Cleve Clin J Med. 73:821–824. 826829–832, passim. 2006. View Article : Google Scholar : PubMed/NCBI
8	Newman RA, Yang P, Pawlus AD and Block KI: Cardiac glycosides as novel cancer therapeutic agents. Mol Interv. 8:36–49. 2008. View Article : Google Scholar : PubMed/NCBI
9	Prassas I and Diamandis EP: Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov. 7:926–935. 2008. View Article : Google Scholar : PubMed/NCBI
10	Takara K, Takagi K, Tsujimoto M, Ohnishi N and Yokoyama T: Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun. 306:116–120. 2003. View Article : Google Scholar : PubMed/NCBI
11	Schoner W: Endogenous cardiac glycosides, a new class of steroid hormones. Eur J Biochem. 269:2440–2448. 2002. View Article : Google Scholar : PubMed/NCBI
12	Schoner W and Scheiner-Bobis G: Endogenous and exogenous cardiac glycosides and their mechanisms of action. Am J Cardiovasc Drugs. 7:173–189. 2007. View Article : Google Scholar : PubMed/NCBI
13	Schoner W and Scheiner-Bobis G: Endogenous and exogenous cardiac glycosides: Their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol. 293:C509–C536. 2007. View Article : Google Scholar : PubMed/NCBI
14	López-Lázaro M: Digitoxin as an anticancer agent with selectivity for cancer cells: Possible mechanisms involved. Expert Opin Ther Targets. 11:1043–1053. 2007. View Article : Google Scholar : PubMed/NCBI
15	Mijatovic T, Van Quaquebeke E, Delest B, Debeir O, Darro F and Kiss R: Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta. 1776:32–57. 2007.PubMed/NCBI
16	Winnicka K, Bielawski K and Bielawska A: Cardiac glycosides in cancer research and cancer therapy. Acta Pol Pharm. 63:109–115. 2006.
17	Svensson A, Azarbayjani F, Bäckman U, Matsumoto T and Christofferson R: Digoxin inhibits neuroblastoma tumor growth in mice. Anticancer Res. 25(1A): 207–212. 2005.PubMed/NCBI
18	Yoshida T, Zhang H, Iwase T, Shen J, Semenza GL and Campochiaro PA: Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J. 24:1759–1767. 2010. View Article : Google Scholar : PubMed/NCBI
19	Abud EM, Maylor J, Undem C, Punjabi A, Zaiman AL, Myers AC, Sylvester JT, Semenza GL and Shimoda LA: Digoxin inhibits development of hypoxic pulmonary hypertension in mice. Proc Natl Acad Sci USA. 109:1239–1244. 2012. View Article : Google Scholar : PubMed/NCBI
20	Wang L, Zheng J, Du Y, Huang Y, Li J, Liu B, Liu CJ, Zhu Y, Gao Y, Xu Q, et al: Cartilage oligomeric matrix protein maintains the contractile phenotype of vascular smooth muscle cells by interacting with alpha(7)beta(1) integrin. Circ Res. 106:514–525. 2010. View Article : Google Scholar
21	Norbury C and Nurse P: Animal cell cycles and their control. Annu Rev Biochem. 61:441–470. 1992. View Article : Google Scholar : PubMed/NCBI
22	Malumbres M and Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 1:222–231. 2001. View Article : Google Scholar
23	Qin J and Wu C: ILK: A pseudokinase in the center stage of cell-matrix adhesion and signaling. Curr Opin Cell Biol. 24:607–613. 2012. View Article : Google Scholar : PubMed/NCBI
24	Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:801–809. 1993. View Article : Google Scholar : PubMed/NCBI
25	Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA and Ross R: Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 253:1129–1132. 1991. View Article : Google Scholar : PubMed/NCBI
26	Glass CK and Witztum JL: Atherosclerosis. the road ahead. Cell. 104:503–516. 2001. View Article : Google Scholar : PubMed/NCBI
27	Contreras RG, Shoshani L, Flores-Maldonado C, Lázaro A and Cereijido M: Relationship between Na(+),K(+)-ATPase and cell attachment. J Cell Sci. 112:4223–4232. 1999.PubMed/NCBI
28	Rajasekaran SA, Palmer LG, Moon SY, Peralta Soler A, Apodaca GL, Harper JF, Zheng Y and Rajasekaran AK: Na,K-ATPase activity is required for formation of tight junctions, desmosomes, and induction of polarity in epithelial cells. Mol Biol Cell. 12:3717–3732. 2001. View Article : Google Scholar : PubMed/NCBI
29	Wang L, Wible BA, Wan X and Ficker E: Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J Pharmacol Exp Ther. 320:525–534. 2007. View Article : Google Scholar
30	Saunders R and Scheiner-Bobis G: Ouabain stimulates endothelin release and expression in human endothelial cells without inhibiting the sodium pump. Eur J Biochem. 271:1054–1062. 2004. View Article : Google Scholar : PubMed/NCBI
31	Abramowitz J, Dai C, Hirschi KK, Dmitrieva RI, Doris PA, Liu L and Allen JC: Ouabain- and marinobufagenin-induced proliferation of human umbilical vein smooth muscle cells and a rat vascular smooth muscle cell line, A7r5. Circulation. 108:3048–3053. 2003. View Article : Google Scholar : PubMed/NCBI
32	Bielawski K, Winnicka K and Bielawska A: Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull. 29:1493–1497. 2006. View Article : Google Scholar : PubMed/NCBI
33	McConkey DJ, Lin Y, Nutt LK, Ozel HZ and Newman RA: Cardiac glycosides stimulate Ca²⁺ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res. 60:3807–3812. 2000.PubMed/NCBI
34	Newman RA, Yang P, Hittelman WN, Lu T, Ho DH, Ni D, Chan D, Vijjeswarapu M, Cartwright C, Dixon S, et al: Oleandrin-mediated oxidative stress in human melanoma cells. J Exp Ther Oncol. 5:167–181. 2006.PubMed/NCBI
35	Newman RA, Kondo Y, Yokoyama T, Dixon S, Cartwright C, Chan D, Johansen M and Yang P: Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr Cancer Ther. 6:354–364. 2007. View Article : Google Scholar : PubMed/NCBI
36	Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B and Schmid RA: Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res. 66:5867–5874. 2006. View Article : Google Scholar : PubMed/NCBI
37	Hallböök H, Felth J, Eriksson A, Fryknäs M, Bohlin L, Larsson R and Gullbo J: Ex vivo activity of cardiac glycosides in acute leukaemia. PloS one. 6:e157182011. View Article : Google Scholar : PubMed/NCBI
38	Kulikov A, Eva A, Kirch U, Boldyrev A and Scheiner-Bobis G: Ouabain activates signaling pathways associated with cell death in human neuroblastoma. Biochim Biophys Acta. 1768:1691–1702. 2007. View Article : Google Scholar : PubMed/NCBI
39	López-Lázaro M, Pastor N, Azrak SS, Ayuso MJ, Austin CA and Cortés F: Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod. 68:1642–1645. 2005. View Article : Google Scholar : PubMed/NCBI
40	Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, et al: Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 99:2164–2170. 1999. View Article : Google Scholar : PubMed/NCBI
41	Sherr CJ and Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
42	Wang SH, Liang CJ, Weng YW, Chen YH, Hsu HY, Chien HF, Tsai JS, Tseng YC, Li CY and Chen YL: Ganoderma lucidum polysaccharides prevent platelet-derived growth factor-stimulated smooth muscle cell proliferation in vitro and neointimal hyperplasia in the endothelial-denuded artery in vivo. J Cell Physiol. 227:3063–3071. 2012. View Article : Google Scholar
43	Guan H, Gao L, Zhu L, Yan L, Fu M, Chen C, Dong X, Wang L, Huang K and Jiang H: Apigenin attenuates neointima formation via suppression of vascular smooth muscle cell phenotypic transformation. J Cell Biochem. 113:1198–1207. 2012. View Article : Google Scholar
44	Gomez D and Owens GK: Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res. 95:156–164. 2012. View Article : Google Scholar : PubMed/NCBI
45	Wang Z, Wang DZ, Hockemeyer D, McAnally J, Nordheim A and Olson EN: Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature. 428:185–189. 2004. View Article : Google Scholar : PubMed/NCBI
46	Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, Yan J, Sanghera J, Walsh MP and Dedhar S: Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: Critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem. 276:27462–27469. 2001. View Article : Google Scholar : PubMed/NCBI
47	Yudowski GA, Efendiev R, Pedemonte CH, Katz AI, Berggren PO and Bertorello AM: Phosphoinositide-3 kinase binds to a proline-rich motif in the Na⁺, K⁺-ATPase alpha subunit and regulates its trafficking. Proc Natl Acad Sci USA. 97:6556–6561. 2000. View Article : Google Scholar
48	Eva A, Kirch U and Scheiner-Bobis G: Signaling pathways involving the sodium pump stimulate NO production in endothelial cells. Biochim Biophys Acta. 1758:1809–1814. 2006. View Article : Google Scholar : PubMed/NCBI
49	Jagielska J, Salguero G, Schieffer B and Bavendiek U: Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: Therapeutic implications for the treatment of atherosclerosis? Atherosclerosis. 206:390–396. 2009. View Article : Google Scholar : PubMed/NCBI
50	Chase AJ and Newby AC: Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: A multi-step recruitment model for pathological remodelling. J Vasc Res. 40:329–343. 2003. View Article : Google Scholar : PubMed/NCBI
51	Johnson JL, Dwivedi A, Somerville M, George SJ and Newby AC: Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler Thromb Vasc Biol. 31:e35–e44. 2011. View Article : Google Scholar : PubMed/NCBI